Dr. Jim Tananbaum- Healthcare Investor, Founder and CEO of Foresite Capital

Jim Tananbaum is the founding Chief Executive Officer of Foresite Capital Management located in bay Area of San Francisco. He has more than 20 years’ experience in healthcare investment. Before founding Foresite, Tananbaum was the founder and manager of 2 top biopharmaceuticals firms, Theravance and GelTex Pharmaceuticals. Jim was also the founding partner of the 2nd and the 3rd Prospect Ventures Partners as well as Sierra Ventures’ partner, both of which are healthcare investment practices. Tananbaum’s main investments consists of Amergroup, Amira Pharmaceuticals, Jazz Pharmaceuticals, and Healtheon.

Educational Background

Jim Tananbaum is a graduate of Harvard Medical School with an M.D. He also graduated from Yale University with a B.S. and B.S.E.E. Furthermore, Jim also attained an M.B.A. from Harvard Business School and MS from MIT. He has served Yale School of Engineering as well as Harvard-MIT HST program on advisory boards and visiting committees.

Mindstrong Health Funded by Investors towards the Treatment and Diagnosis of Neuropsych

Mndstrong Health secured $14 million from investors towards the diagnosis and treatment of mental disorders through neuropsychiatric. The funding was led by Foresite Capital and ARCH Ventures. It was later joined by Berggruen Holdings, Optum Ventures as well as the One Mind Brain Health Impact fund, as stated by the Calif-based company, Palo Alto. The company aims to offer sustained digital biomarkers of cognition and mood through Google smartphone devices that are neurologically-specialized. The device is intended for observing interaction arrangements on smartphones to measure the function of the brain accurately.

Objective Measures in treatment of Mental Disorders

 In his set statement, Jim Tananbaum, the founder and CEO of Foresite Capital, said that the founding team of Mindstrong Health provides supreme awareness of the critical encounters involving the means through which the medical sector provide attention to cognitive health disorders’ patients. He continued by saying that technical vision, leadership, and collective experience of individuals mandated with improving the outcome of patients, will benefit from an inventive platform that not only improves but also massively advances the means through which care is delivered. Mindstrong Health CEO and founder, Paul Dagum, affirmed that firms’ objective is to tackle mental disorders using objective measures.

Comments are disabled